384 related articles for article (PubMed ID: 37117135)
1. Immune mechanisms of toxicity from checkpoint inhibitors.
Wang SJ; Dougan SK; Dougan M
Trends Cancer; 2023 Jul; 9(7):543-553. PubMed ID: 37117135
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
Baik AH; Tsai KK; Oh DY; Aras MA
Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
[TBL] [Abstract][Full Text] [Related]
3. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
Okiyama N; Tanaka R
Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
Yao L; Jia G; Lu L; Bao Y; Ma W
Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
[TBL] [Abstract][Full Text] [Related]
5. Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach.
Del Gaudio A; Di Vincenzo F; Petito V; Giustiniani MC; Gasbarrini A; Scaldaferri F; Lopetuso LR
Inflamm Bowel Dis; 2024 Jun; 30(6):1018-1031. PubMed ID: 37801695
[TBL] [Abstract][Full Text] [Related]
6. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
7. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
Goleva E; Lyubchenko T; Kraehenbuehl L; Lacouture ME; Leung DYM; Kern JA
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):630-638. PubMed ID: 33716146
[TBL] [Abstract][Full Text] [Related]
8. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():1956. PubMed ID: 32983126
[TBL] [Abstract][Full Text] [Related]
9. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
10. Toxicities associated with immune checkpoint inhibitors: a systematic study.
Kong X; Chen L; Su Z; Sullivan RJ; Blum SM; Qi Z; Liu Y; Huo Y; Fang Y; Zhang L; Gao J; Wang J
Int J Surg; 2023 Jun; 109(6):1753-1768. PubMed ID: 37132038
[TBL] [Abstract][Full Text] [Related]
11. Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.
Li N; Wang G; Hou X; Tai R; Huang S; He Z; Lei L; Xu S; Yang S
Int Immunopharmacol; 2022 Jul; 108():108803. PubMed ID: 35569432
[TBL] [Abstract][Full Text] [Related]
12. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
13. Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models.
Park BC; Stone CA; Dewan AK; Johnson DB
Immunol Allergy Clin North Am; 2022 May; 42(2):285-305. PubMed ID: 35469619
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors.
Hu X; Wang L; Shang B; Wang J; Sun J; Liang B; Su L; You W; Jiang S
Front Immunol; 2023; 14():1094414. PubMed ID: 36949956
[TBL] [Abstract][Full Text] [Related]
15. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors.
Teng YS; Yu S
Curr Oncol; 2023 Jul; 30(7):6805-6819. PubMed ID: 37504358
[TBL] [Abstract][Full Text] [Related]
18. Understanding and treating the inflammatory adverse events of cancer immunotherapy.
Dougan M; Luoma AM; Dougan SK; Wucherpfennig KW
Cell; 2021 Mar; 184(6):1575-1588. PubMed ID: 33675691
[TBL] [Abstract][Full Text] [Related]
19. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Naimi A; Mohammed RN; Raji A; Chupradit S; Yumashev AV; Suksatan W; Shalaby MN; Thangavelu L; Kamrava S; Shomali N; Sohrabi AD; Adili A; Noroozi-Aghideh A; Razeghian E
Cell Commun Signal; 2022 Apr; 20(1):44. PubMed ID: 35392976
[TBL] [Abstract][Full Text] [Related]
20. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
